Predominant Genotypes and Alleles of Two Functional Polymorphisms in the Manganese Superoxide Dismutase Gene are Not Associated with Thai Cervical or Breast Cancer

  • Published : 2013.06.30


Background: Defects of manganese superoxide dismutase (MnSOD) have long been implicated in generation of oxidative stress and risk susceptibility to various cancers. Two functional polymorphisms within the MnSOD gene, including the Val-9Ala of the mitochondrial targeting sequence (MTS) and the Ile58Thr of the exon-3, have been proposed to reduce its enzyme activity and antioxidant potential. Materials and Methods: A high-throughput multiplex SNaPshot$^{(R)}$ system was developed herein for simultaneous analyses of Val-9Ala and Ile58Thr in a single reaction. Genomic DNA extracted from each whole blood sample of 248 patients including 107 with cervical cancer and 141 with breast cancer and from 136 healthy women as controls was analyzed by the multiplex SNaPshot$^{(R)}$ system. Results: The Val/Val, Val/Ala genotypes and the Val allele of the MTS were predominant in patients with cervical or breast cancer as well as healthy women in Thailand. The Ile/Ile genotype and the Ile allele of the exon-3 were found in all of them whereas none of the Ile/Thr, the Thr/Thr genotypes and the Thr allele was detected. Genotypic association of both Val-9Ala and Ile58Thr polymorphisms with cervical cancer and breast cancer of these patients comparing to healthy women was not statistically significant (p<0.05). Conclusions: The Val/Val, Val/Ala genotypes and the Val allele of the MTS were found predominantly but the Ile/Ile genotype and the Ile allele of the exon-3 were detected in patients with cervical cancer, breast cancer and healthy women in Thailand. These two functional polymorphisms (Val-9Ala and Ile58Thr) in MnSOD gene did not associate with susceptibility risk of these cancer patients in Thailand.


  1. Attatippaholkun W, Wikainapakul K, Waikakul S, et al (2012). Predominant genotypes and alleles of the Val-9Ala polymorphisms in the mitochondrial targeting sequence leading the manganese superoxide dismutase gene associated with superoxide dismutase activity and total antioxidant status of healthy Thai subjects. Thai J Genet, 5, 86-101.
  2. Akyol O, Canatan H, Yilmaz HR, et al (2004). PCR/RFLP based cost-effective identification of SOD2 signal (leader) sequence polymorphism (Ala-9Val) using NgoMIV: a detailed methodological approach. Clin Chim Acta, 345, 151-9.
  3. Bag A, Bag N (2008). Target sequence polymorphism of human manganese superoxide dismutase gene and its association with cancer risk: a review. Cancer Epidemiol Biomarkers Prev, 17, 3298-305.
  4. Bastaki M, Huen K, Manzanillo P, et al (2006). Genotype-activity relationship for Mn-superoxide dismutase, gluthathione peroxidase 1 and catalase in humans. Pharmacogenet Genomics, 16, 279-86.
  5. Boom R, Sol CJ, Salimans MM, et al (1996). Rapid and simple method for purification of nucleic acids. J Clin Microbiol, 28, 495-503.
  6. Borgstahl GEO, Parge HE, Hickey MJ, et al (1996). Human mitochondrial manganese superoxide dismutase polymorphic variant Ile58Thr reduces activity by destabilizing the tetrameric interface. Biochemistry, 35, 4287-97.
  7. Chistyakov DA, Savostanov KV, Zotova EV, et al (2001). Polymorphisms in the MnSOD and EC-SOD genes and their relationship to diabetic neuropathy in type I diabetes mellitus. BMC Med Gen, 2, 1-4.
  8. Church SL, Grant JW, Meese EU, et al (1992). Sublocalization of the gene encoding manganese superoxide dismutase (MnSOD/SOD2) to 6q25 by fluorescence in situ hydridization and somatic cell hybrid mapping. Genomics, 14, 823-5.
  9. Elsakka NE, Webster NR, Galley HF, (2007). Polymorphisms in the manganese superoxide dismutase gene. Free Rad Res, 41, 770-8.
  10. Ezzikouri S, El Feydi AE, Chafik A (2008). Genetic polymorphism in the manganese superoxide dismutase gene is associated with an increased risk for hepatocellular carcinoma in HCVinfected Moroccan patients. Mutation Res, 649, 1-6.
  11. Fujimoto H, Taguchi J, Imai Y, et al (2008). Manganese superoxide dismutase polymorphism affects the oxidized low-density lipoprotein-induced apoptosis of macrophages and coronary artery disease. Eur Heart J, 29, 1267-74.
  12. Galecki P, Smigielski J, Florkowski A, et al (2010). Analysis of two polymorphisms of the manganese superoxide dismutase gene (Ile-58Thr and Ala-9Val) in patients with recurrent depressive disorder. Psychiatry Res, 179, 43-6.
  13. Grasbon-Frodl EM, Kosel S, Riess O, et al (1999). Analysis of Mitochondrial targeting sequence and coding region polymorphisms of the manganese superoxide dismutase gene in German Parkinson disease patients. Biochem Biophys Res Commun, 255, 749-52.
  14. Halliwell B (2007). Oxidative stress and cancer: have we moved forward? Biochem J, 401, 1-11.
  15. Han J, Colditz GA, Hunter DJ (2007). Manganese superoxide dismutase polymorphism and risk of skin cancer (United States). Cancer Causes Control, 18, 79-89.
  16. Hiroi S, Harada H, Nishi H, et al (1999). Polymorphisms in the SOD2 and HLA-DRB1 genes are associated with nonfamilial idiopathic dilated cardiomyopathy in Japanese. Biochem Biophys Res Commun, 261, 332-9.
  17. Hitzeroth A, Niehaus DJ, Koen L, et al (2007). Association between the MnSOD Ala-9Val polymorphism and development of schizophrenia and abnormal involuntary movements in the Xhosa population. Prog Neuropsychopharmacol Bio Psychiatry, 31, 664-72.
  18. Ho JC, Mak JC, Ho SP, et al (2006). Manganese superoxide dismutase and catalase genetic polymorphisms, activity levels, and lung cancer risk in Chinese in Hong Kong. J Thorac Oncol, 1, 648-53.
  19. Johnatty SE, Nagle CM, Spurdle AB, et al (2007). Australian Breast Cancer Family Study. The MnSOD Val-9Ala polymorphism, dietary antioxidant intake, risk and survival in ovarian cancer (Australia). Gynecol Oncol, 107, 388-91.
  20. Kakko S, Paivansalo M, Koistinen P, et al (2003). The signal sequence polymorphism of the MnSOD gene is associated with the degree of carotid atherosclerosis. Atherosclerosis, 168, 147-52.
  21. Kannan K, Jain SK (2000). Oxidative stress and apoptosis. Pathophysiology, 7, 153-63.
  22. Khuhaprema T (2008). Current cancer situation in Thailand. Thai J Toxicology, 23, 60-1.
  23. Knight JA, Onay UV, Wells S, et al (2004). Genetic variants of GPX1 and SOD2 and breast cancer risk at the Ontario site of the breast cancer family registry. Cancer Epidemiol Biomark Prev, 13, 146-9.
  24. Kregel KC, Zhang HJ (2007). An integrated view of oxidative stress in aging: basic mechanisms, functional effects, and pathological considerations. Am J Physiol Regul Comp Physiol, 292, 18-36.
  25. Martin RCG, Lan Q, Hughes K, et al (2005). No apparent association between genetic polymorphisms (-102 C>T) and (-9 T>C) in the human manganese superoxide dismutase gene and gastric cancer. J Surg Res, 124, 92-7.
  26. Mikhak B, Hunter DJ, Spiegelman D, et al (2008). Manganese superoxide dismutase (MnSOD) gene polymorphism, interactions with carotenoid levels, and prostate cancer risk. Carcinogenesis, 29, 2335-40.
  27. Murphy SJ, Hughes AE, Patterson CC, et al (2007). A populationbased association study of SNPs of GSTP1, MnSOD, GPX2 and Barrett's esophagus and esophageal adenocarcinoma. Carcinogenesis, 28, 1323-8.
  28. Osterreicher CH, Schultheiss J, Wehler M, et al (2007). Genetic polymorphisms of manganese- superoxide dismutase and glutathione-S-transferase in chronic alcoholic pancreatitis. Mutagenesis, 22, 305-10.
  29. Pae CU, Kim TS, Patkar AA, et al (2007). Manganese superoxide dismutase (MnSOD: Ala-9Val) gene polymorphism may not be associated with schizophrenia and tardive dyskinesia. Psychiatry Res, 153, 77-81.
  30. Parboosingh JS, Rousseau M, Rogan F, et al (1995). Absence of mutations in superoxide dismutase and catalase genes in patients with Parkinson's disease. Arch Neurol, 52, 1160-3.
  31. Rosenblum JS, Gilula NB, Lerner RA (1996). On signal sequence polymorphism and disease of distribution. Proc Natl Acad Sci USA, 93, 4471-3.
  32. Sanger F, Nicklen S, Coulson AR (1977). DNA sequencing with chain terminating inhibitors. Proc Natl Acad Sci USA, 74, 5463-7.
  33. Shimoda-Matsubayashi S, Matsumine H, Kobayashi T, et al (1996). Structural dimorphism in the mitochondrial targeting sequence in the human manganese superoxide dismutase gene. A predictive evidence for conformational change to influence mitochondrial transport and a study of allelic association in Parkinson's disease. Biochem Biophys Res Commun, 226, 561-5.
  34. Sutton A, Khoury H, Prip-Buus C, et al (2003). The Ala16Val genetic dimorphism modulates the import of human manganese superoxide dismutase into rat liver mitochondria. Pharmacogenetics, 13, 145-57.
  35. Sutton A, Imbert A, Igoudjil A, et al (2005). The manganese superoxide dismutase Ala16Val dimorphism modulates both mitochondrial import and mRNA stability. Pharmacogenet Genomics, 15, 311-9.
  36. Ventriglia M, Scassellati C, Bonvicini C, et al (2006). No association between Ala9Val functional polymorphism of MnSOD gene and schizophrenia in a representative Italian sample. Neurosci Lett, 410, 208-11.
  37. Wan XS, Devalaraja MN, St Clair DK (1994). Molecular structure and organization of the human manganese superoxide dismutase gene. DNA Cell Biol, 13, 1127-36.
  38. Wang V, Chen SY, Chuang TC, et al (2010). Val-9Ala and Ile58Thr polymorphism of MnSOD in Parkinson's disease. Clin Biochem, 43, 979-82.
  39. Wu LL, Chiou CC, Chang PY, et al (2007). Urinary 8-OHdG: a marker of oxidative stress to DNA and a risk factor for cancer, atherosclerosis and diabetics. Clin Chim Acta, 339, 1-9.
  40. Zejnilovic J, Akev N, Yilmaz H, et al (2009). Association between manganese superoxide dismutase polymorphism and risk of lung cancer. Cancer Genetics Cytogenetics, 189, 1-4.
  41. Zhang HJ, Yan T, Oberley TD, et al (1999). Comparison of effects of two polymorphic variants of manganese superoxide dismutase on human breast MCF-7 cancer cell phenotype. Cancer Res, 59, 6276-83.

Cited by

  1. Manganese Superoxide Dismutase (MnSOD Val-9Ala) Gene Polymorphism and Susceptibility to Gastric Cancer vol.16, pp.2, 2015,
  2. There is no relationship between SOD2 Val-16Ala polymorphism and breast cancer risk or survival vol.7, pp.4, 2017,
  3. Val16Ala Polymorphism and Cancer Risk: Evidence from 33,098 Cases and 37,831 Controls vol.2018, pp.1875-8630, 2018,